Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD
Phase of Trial: Phase I/II
Latest Information Update: 12 Jul 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms GITMO; Nilo-cGVHD
- 31 Aug 2018 Biomarkers information updated
- 02 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to recruiting.